http://purl.org/np/RAMDo1uV4osMyL1h1sdF7oV__yeXMqzIrnLlN3kjAwimo#Head http://purl.org/np/RAMDo1uV4osMyL1h1sdF7oV__yeXMqzIrnLlN3kjAwimo http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAMDo1uV4osMyL1h1sdF7oV__yeXMqzIrnLlN3kjAwimo#assertion http://purl.org/np/RAMDo1uV4osMyL1h1sdF7oV__yeXMqzIrnLlN3kjAwimo http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAMDo1uV4osMyL1h1sdF7oV__yeXMqzIrnLlN3kjAwimo#provenance http://purl.org/np/RAMDo1uV4osMyL1h1sdF7oV__yeXMqzIrnLlN3kjAwimo http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAMDo1uV4osMyL1h1sdF7oV__yeXMqzIrnLlN3kjAwimo#pubinfo http://purl.org/np/RAMDo1uV4osMyL1h1sdF7oV__yeXMqzIrnLlN3kjAwimo http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAMDo1uV4osMyL1h1sdF7oV__yeXMqzIrnLlN3kjAwimo#assertion http://purl.obolibrary.org/obo/DOID_5419 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAMDo1uV4osMyL1h1sdF7oV__yeXMqzIrnLlN3kjAwimo#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_5419 http://purl.org/np/RAMDo1uV4osMyL1h1sdF7oV__yeXMqzIrnLlN3kjAwimo#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAMDo1uV4osMyL1h1sdF7oV__yeXMqzIrnLlN3kjAwimo#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB01224 http://purl.org/np/RAMDo1uV4osMyL1h1sdF7oV__yeXMqzIrnLlN3kjAwimo#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAMDo1uV4osMyL1h1sdF7oV__yeXMqzIrnLlN3kjAwimo#association http://www.w3.org/2000/01/rdf-schema#label seroquel xr is an atypical antipsychotic indicated for the treatment of schizophrenia 1 1 adults efficacy was established with seroquel xr in one 6 week and one maintenance trial in patients with schizophrenia as well as in three 6 week trials with seroquel in patients with schizophrenia 14 1 acute treatment of manic or mixed episodes associated with bipolar i disorder both as monotherapy and as an adjunct to lithium or divalproex 1 2 adults efficacy was established with seroquel xr in one 3 week trial in patients with manic or mixed episodes associated with bipolar i disorder as well as two 12 week monotherapy trials and one 3 week adjunctive trial with seroquel in patients with manic episodes associated with bipolar i disorder 14 2 acute treatment of depressive episodes associated with bipolar disorder 1 2 adults efficacy was established with seroquel xr in one 8 week trial in patients with bipolar i or ii disorder as well as two 8 week trials with seroquel in patients with bipolar i or ii disorder 14 2 maintenance treatment of bipolar i disorder as an adjunct to lithium or divalproex 1 2 adults efficacy was established with seroquel in two maintenance trials in patients with bipolar i disorder 14 2 adjunctive treatment of major depressive disorder mdd 1 3 adults efficacy as an adjunct to antidepressants was established in two 6 week trials in patients with mdd who had an inadequate response to an antidepressant alone 14 3 seroquel xr is indicated for the treatment of schizophrenia the efficacy of seroquel xr in schizophrenia was established in one 6 week and one maintenance trial in adults with schizophrenia as well by extrapolation from three 6 week trials in adults with schizophrenia treated with seroquel see clinical studies seroquel xr is indicated for the acute treatment of manic or mixed episodes associated with bipolar i disorder both as monotherapy and as an adjunct to lithium or divalproex the efficacy of seroquel xr in manic or mixed episodes of bipolar i disorder was established in one 3 week trial in adults with manic or mixed episodes associated with bipolar i disorder as well by extrapolation from two 12 week monotherapy and one 3 week adjunctive trial in adults with manic episodes associated with bipolar i disorder treated with seroquel see clinical studies seroquel xr is indicated for the acute treatment of depressive episodes associated with bipolar disorder the efficacy of seroquel xr was established in one 8 week trial in adults with bipolar i or ii disorder as well as extrapolation from two 8 week trials in adults with bipolar i or ii disorder treated with seroquel see clinical studies seroquel xr is indicated for the maintenance treatment of bipolar i disorder as an adjunct to lithium or divalproex efficacy was extrapolated from two maintenance trials in adults with bipolar i disorder treated with seroquel the effectiveness of monotherapy for the maintenance treatment of bipolar disorder has not been systematically evaluated in controlled clinical trials see clinical studies seroquel xr is indicated for use as adjunctive therapy to antidepressants for the treatment of mdd the efficacy of seroquel xr as adjunctive therapy to antidepressants in mdd was established in two 6 week trials in adults with mdd who had an inadequate response to antidepressant treatment see clinical studies http://purl.org/np/RAMDo1uV4osMyL1h1sdF7oV__yeXMqzIrnLlN3kjAwimo#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAMDo1uV4osMyL1h1sdF7oV__yeXMqzIrnLlN3kjAwimo#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAMDo1uV4osMyL1h1sdF7oV__yeXMqzIrnLlN3kjAwimo#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB01224 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAMDo1uV4osMyL1h1sdF7oV__yeXMqzIrnLlN3kjAwimo#provenance http://purl.org/np/RAMDo1uV4osMyL1h1sdF7oV__yeXMqzIrnLlN3kjAwimo#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAMDo1uV4osMyL1h1sdF7oV__yeXMqzIrnLlN3kjAwimo#pubinfo http://purl.org/np/RAMDo1uV4osMyL1h1sdF7oV__yeXMqzIrnLlN3kjAwimo#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAMDo1uV4osMyL1h1sdF7oV__yeXMqzIrnLlN3kjAwimo#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAMDo1uV4osMyL1h1sdF7oV__yeXMqzIrnLlN3kjAwimo#sig http://purl.org/nanopub/x/hasSignature P8jfgkiIpRZeMDXhKrcvfV+VkFTJk/0huU+lXWmZn2lPfgc8O+3viHV5lstMrJfpGYgQSonpW0OEAlfdf4SXyZBEKa2kJkBaO7//iXejd/nMoIO6SP+yyYtitqiWUPzXLLgseUo0r4y5RfrmSIWa/83YF9m+s83muq96Yzk6nDs= http://purl.org/np/RAMDo1uV4osMyL1h1sdF7oV__yeXMqzIrnLlN3kjAwimo#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAMDo1uV4osMyL1h1sdF7oV__yeXMqzIrnLlN3kjAwimo http://purl.org/np/RAMDo1uV4osMyL1h1sdF7oV__yeXMqzIrnLlN3kjAwimo http://purl.org/dc/terms/created 2021-06-13T16:05:50.956+02:00 http://purl.org/np/RAMDo1uV4osMyL1h1sdF7oV__yeXMqzIrnLlN3kjAwimo http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAMDo1uV4osMyL1h1sdF7oV__yeXMqzIrnLlN3kjAwimo https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAMDo1uV4osMyL1h1sdF7oV__yeXMqzIrnLlN3kjAwimo https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAMDo1uV4osMyL1h1sdF7oV__yeXMqzIrnLlN3kjAwimo https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs